BENITEC BIOPHARMA INC.
Income Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $75.0K | $73.0K | $59.0K | $102.0K | $12.2M |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $15.6M | $12.8M | $11.3M | $7.0M | $3.0M | $4.6M |
| SG&A Expense | $7.0M | $6.4M | $6.6M | $6.5M | $5.6M | $4.6M |
| Operating Income | $-22.5M | $-19.1M | $-17.9M | $-13.6M | $-8.3M | $2.6M |
| Operating Margin | — | -25,441.3% | -24,457.5% | -23,044.1% | -8,118.6% | 21.2% |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — |
| Net Income | $-21.8M | $-19.6M | $-18.2M | $-13.9M | $-8.3M | $2.6M |
| Net Margin | — | -26,082.7% | -24,942.5% | -23,528.8% | -8,111.8% | 21.4% |
| EPS (Basic) | $-1.22 | $-1.09 | $-0.97 | $-0.08 | $-0.21 | $0.08 |
| EPS (Diluted) | $-1.22 | $-1.09 | $-0.97 | $-0.08 | $-0.21 | $0.08 |
| Shares Outstanding (Basic) | 18.4M | 18.0M | 18.7M | 167.5M | 43.2M | 33.4M |
| Shares Outstanding (Diluted) | 18.4M | 18.0M | 18.7M | 167.5M | 43.2M | 33.4M |
| Dividends Per Share | — | — | — | — | — | — |